These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38312665)

  • 1. Dual-targeting CD44 and mucin by hyaluronic acid and 5TR1 aptamer for epirubicin delivery into cancer cells: Synthesis, characterization,
    Jamshidi Z; Dehghan R; Nejabat M; Abnous K; Taghdisi SM; Hadizadeh F
    Heliyon; 2024 Jan; 10(2):e24833. PubMed ID: 38312665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells.
    Moosavian SA; Abnous K; Akhtari J; Arabi L; Gholamzade Dewin A; Jafari M
    Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):2054-2065. PubMed ID: 29205059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smart aptamer-modified calcium carbonate nanoparticles for controlled release and targeted delivery of epirubicin and melittin into cancer cells in vitro and in vivo.
    Yazdian-Robati R; Arab A; Ramezani M; Rafatpanah H; Bahreyni A; Nabavinia MS; Abnous K; Taghdisi SM
    Drug Dev Ind Pharm; 2019 Apr; 45(4):603-610. PubMed ID: 30633594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-targeted delivery system using hollow silica nanoparticles with H
    Mirzaei S; Khademi Z; Zolfaghari R; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
    Drug Dev Ind Pharm; 2023 Oct; 49(10):648-657. PubMed ID: 37772892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery.
    Taghavi S; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
    Cancer Lett; 2017 Aug; 400():1-8. PubMed ID: 28412238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells.
    Hanafi-Bojd MY; Moosavian Kalat SA; Taghdisi SM; Ansari L; Abnous K; Malaekeh-Nikouei B
    Drug Dev Ind Pharm; 2018 Jan; 44(1):13-18. PubMed ID: 28832225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of epirubicin to cancerous cell using copper sulphide nanoparticle coated with polyarginine and 5TR1 aptamer.
    Alizadeh F; Yaghoobi E; Imanimoghadam M; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
    J Drug Target; 2023 Dec; 31(9):986-997. PubMed ID: 37869893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo.
    Taghdisi SM; Danesh NM; Ramezani M; Lavaee P; Jalalian SH; Robati RY; Abnous K
    Eur J Pharm Biopharm; 2016 May; 102():152-8. PubMed ID: 26987703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo.
    Jalalian SH; Taghdisi SM; Shahidi Hamedani N; Kalat SA; Lavaee P; Zandkarimi M; Ghows N; Jaafari MR; Naghibi S; Danesh NM; Ramezani M; Abnous K
    Eur J Pharm Sci; 2013 Oct; 50(2):191-7. PubMed ID: 23835028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.
    Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM
    Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer.
    Mansoori-Kermani A; Khalighi S; Akbarzadeh I; Niavol FR; Motasadizadeh H; Mahdieh A; Jahed V; Abdinezhad M; Rahbariasr N; Hosseini M; Ahmadkhani N; Panahi B; Fatahi Y; Mozafari M; Kumar AP; Mostafavi E
    Mater Today Bio; 2022 Dec; 16():100349. PubMed ID: 35875198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Delivery of Epirubicin to Cancer Cells by Polyvalent Aptamer System in vitro and in vivo.
    Yazdian-Robati R; Ramezani M; Jalalian SH; Abnous K; Taghdisi SM
    Pharm Res; 2016 Sep; 33(9):2289-97. PubMed ID: 27283831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-targeted and controlled release delivery of doxorubicin to breast adenocarcinoma: In vitro and in vivo studies.
    Jamshidi Z; Sadat Zavvar T; Ramezani M; Alibolandi M; Hadizadeh F; Abnous K; Taghdisi SM
    Int J Pharm; 2022 Jul; 623():121892. PubMed ID: 35671850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual targeting of Mg/N doped-carbon quantum dots with folic and hyaluronic acid for targeted drug delivery and cell imaging.
    Ziaee N; Farhadian N; Abnous K; Matin MM; Khoshnood A; Yaghoobi E
    Biomed Pharmacother; 2023 Aug; 164():114971. PubMed ID: 37295246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted co-delivery of epirubicin and NAS-24 aptamer to cancer cells using selenium nanoparticles for enhancing tumor response in vitro and in vivo.
    Jalalian SH; Ramezani M; Abnous K; Taghdisi SM
    Cancer Lett; 2018 Mar; 416():87-93. PubMed ID: 29253524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smart delivery of epirubicin to cancer cells using aptamer-modified ferritin nanoparticles.
    Yazdian-Robati R; Bayat P; Dehestani S; Hashemi M; Taghdisi SM; Abnous K
    J Drug Target; 2022 Jun; 30(5):567-576. PubMed ID: 34991424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The application of aptamer 5TR1 in triple negative breast cancer target therapy.
    Luo S; Wang S; Luo N; Chen F; Hu C; Zhang K
    J Cell Biochem; 2018 Jan; 119(1):896-908. PubMed ID: 28671278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dual-targeted hyaluronic acid-gold nanorod platform with triple-stimuli responsiveness for photodynamic/photothermal therapy of breast cancer.
    Xu W; Qian J; Hou G; Wang Y; Wang J; Sun T; Ji L; Suo A; Yao Y
    Acta Biomater; 2019 Jan; 83():400-413. PubMed ID: 30465921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonspecific nuclear uptake of anti-MUC1 aptamers by dead cells: the role of cell viability monitoring in aptamer targeting of membrane-bound protein cancer biomarkers.
    Flanagan SP; Fogel R; Edkins AL; Ho LSJ; Limson J
    Anal Methods; 2021 Mar; 13(9):1191-1203. PubMed ID: 33605950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
    Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
    Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.